Haemonetics Beats Expectations in Q3 Earnings
Update: 2025-11-06
Description
Haemonetics, a blood products specialist, reported robust Q3 earnings, surpassing Wall Streets expectations with a non-GAAP profit per share of $1.27, a 14% increase. Despite a slight revenue dip, the company raised its full-year adjusted earnings per share guidance to $4.09, and improved its operating margin to 17.9%. Free cash flow margin also saw a significant boost, rising to 32.5%. The stock responded positively, trading up by 12.8% to $57.23.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
